Poster Presenter

Saturday, June 1, 2013: 12:00 PM-3:15 PM
P2
The Role Of Vitamin D In Optic Neuritis
Jodie M Burton, MD, MSc, FRCPC, University of Calgary; Jessie Trufyn, BSc, University of Calgary; Cheslia Tung, BSc candidate, University of Calgary; Misha Eliasziw, PhD, Tufts University; Fiona Costello, MD, FRCPC, University of Calgary

P3
Autologous Haematopoietic Stem Cell Transplant In Patients With Neuromyelitis Optica
Jodie M Burton, MD, MSc, FRCPC, University of Calgary; Jan Storek, PhD, MD, FRCPC, University of Calgary; Peter Duggan, MD, FRCPC, University of Calgary; Fiona Costello, MD, FRCPC, University of Calgary; Donna Genest, RN, University of Calgary; Robert Bell, MD, FRCPC, University of Calgary; Luanne Metz, MD, FRCPC, University of Calgary

P5
Teriflunomide Efficacy and Safety Analyses: Results From TEMSO and TOWER
Mark Freedman, MD, University of Ottawa; Christian Confavreux, MD, University Claude Bernard, Lyon, France; Tomas Olsson, MD, Karolinska Institute; Giancarlo Comi, MD, University Vita-Salute San Raffaele; Aaron Miller, MD, Mount Sinai School of Medicine; Jerry Wolinsky, MD, University of Texas Health Science Center; Ludwig Kappos, MD, University Hospital, Basel Neurology, Basel, Switzerland; Hadj Benzerdjeb, MD, Sanofi; Deborah Dukovic, MS, Sanofi; Philippe Truffinet, MD, Sanofi; Paul O'Connor, MD, University of Toronto

P6
The Effect Of IV MP (Methylprednisolone) On Glucose and Blood Pressure In MS Patients
Malcolm H Gottesman, MD, Winthrop University Hospital; Patricia A Patrick, DrPH, Winthrop University Hospital; Denise Cheng, RN, Winthrop University Hospital; Eileen Boylan, RN, Winthrop University Hospital; Abigail McNall, FNP, Winthrop University Hospital; Sharon Friedman-Urevich, DNP, Winthrop University Hospital; Shicong Ye, MD, Winthrop University Hospital; Johanna Guardado, RN, Winthrop University Hospital

P7
Viral and Genetic Risk Factors For Pediatric Neuromyelitis Optica
Sirisha Grandhe, BA, University of California, San Francisco; Jennifer Graves, MD, PhD, University of California, San Francisco; Ellen M Mowry, MD, University of California, San Francisco; Lauren Krupp, MD, Stony Brook University Medical Center; Tanuja Chitnis, MD, Massachusetts General Hospital; Eluen A Yeh, MD, Hospital for Sick Children; Nancy Kuntz, MD, Ann & Robert H. Lurie Children's Hospital of Chicago; Jayne Ness, MD, Children's Hospital Alabama; Anita L Belman, MD, Stony Brook University Medical Center; Maria Milazzo, NP, Stony Brook University Medical Center; Mark Gorman, MD, Boston Children's Hospital; Bianca Weinstock-Guttman, MD, University of Buffalo; Moses Rodriguez, MD, Mayo Clinic; Marc Patterson, MD, Mayo Clinic; Judith A James, MD, Oklahoma Medical Research Foundation, University of Oklahoma; Emmanuelle Waubant, MD, PhD, University of California, San Francisco

P8
Selective Deletion of S1P5 Receptors Reduces Remyelination in the Curprizone Model
Audrey Gray, MS, EMD Serono Research Institute; Dongzi Yu, MS, EMD Serono Research Institute; Dan Crawford, PhD, EMD Serono Research Institute; Frederic Bernard, PhD, EMD Serono Research Institute; Ursula Boschert, PhD, EMD Serono Research Institute; Tammy Dellovade, PhD, EMD Serono Research Institute; Danielle Graham, PhD, EMD Serono Research Institute

P9
The Effect Of Walking Impairment Of Multiple Sclerosis Patients On Caregiver Burden
Ozge Ertekin, PT PhD, Assist.Prof., Sifa University Faculty of Health Sciences; Serkan Ozakbas, Professor Of Neurology, Dokuz Eylul University; Egemen Idiman, Professor Of Neurology, Dokuz Eylul University

P10
Pragmatic Exercise For People With MS: A Randomized Controlled Trial
John M Saxton, PhD, University of East Anglia; Anouska Carter, MSc, Sheffield Hallam University; Amanda Daley, PhD, University of Birmingham; Liam Humphreys, MSc, Sheffield Hallam University; Nicky Snowdon, MSc, Sheffield Hallam University; Nicola Woodroofe, PhD, Sheffield Hallam University; Jane Petty, BSc (Hons), London; Andrea Roalfe, MSc, University of Birmingham; Basil Sharrack, MD, Sheffield Teaching Hospitals NHS Foundation Trust

P11
Risk factors for transverse myelitis compared with multiple sclerosis, neuromyelitis optica, and other neurologic disorders in pediatric patients
Kelley M Weinfurtner, B.A., University of California-San Francisco; Jennifer Graves, MD, PhD, University of California, San Francisco; Ellen M Mowry, MD, University of California, San Francisco; Lauren Krupp, MD, Stony Brook University Medical Center; Tanuja Chitnis, MD, Massachusetts General Hospital; E Ann Yeh, MD, Hospital for Sick Children, University of Toronto; Moses Rodriguez, MD, Mayo Clinic; Jayne Ness, MD, Children's Hospital Alabama; Anita L Belman, MD, Stony Brook University Medical Center; Marc Patterson, MD, Mayo Clinic; Mark Gorman, MD, Boston Children's Hospital; Bianca Weinstock-Guttman, MD, State University of New York at Buffalo, Buffalo; Judith A James, MD, Oklahoma Medical Research Foundation, University of Oklahoma; Emmanuelle Waubant, MD, PhD, University of California, San Francisco

P12
Profiling Of Secondary Progressive Multiple Sclerosis By Multicolor Flow Cytometry
Lauren W Collison, Ph.D., Opexa Therapeutics, Inc.; Chris L Ayers, Ph.D., Opexa Therapeutics, Inc.; Jordan L Harrell, M.B.E., Opexa Therapeutics, Inc.; Jaye L Thompson, Ph.D., Opexa Therapeutics, Inc.; Don G Healey, Ph.D., Opexa Therapeutics, Inc.

P13
Consequences Of Different Definitions Of Confirmed Disability Progression
Ron Hashmonay, MD, Novartis Pharmaceuticals Corporation; Niklas Bergvall, PhD, Novartis Pharma AG; Nikolaos Sfikas, PhD, Novartis Pharma AG; Peter Chin, MD, Novartis Pharmaceuticals Corporation; Philipp von Rosenstiel, MD, Novartis Pharma AG

P14
Walking and Cognition, But Not Symptoms, Correlate With Dual Task Cost Of Walking In MS
Robert W Motl, PhD, University of Illinois at Urbana-Champaign; Jacob J Sosnoff, PhD, University of Illinois at Urbana-Champaign; Deirdre Dlugonski, BS, University of Illinois at Urbana-Champaign; Lara A Pilutti, PhD, University of Illinois at Urbana-Champaign; Rachel E Klaren, BS, University of Illinois at Urbana-Champaign; Brian M Sandroff, MS, University of Illinois at Urbana-Champaign

P15
Recurrent Falls In Older Adults With MS
Jacob J Sosnoff, PhD, University of Illinois at Urbana-Champaign; Swathi Balantrapu, BS, University of Illinois at Urbana-Champaign; Brian M Sandroff, MS, University of Illinois at Urbana-Champaign; Lara A Pilutti, PhD, University of Illinois at Urbana-Champaign; Steve Morrison, PhD, Old Dominion Unviersity; Robert W Motl, PhD, University of Illinois at Urbana-Champaign

P16
Magnetic Resonance Imaging In The Cuprizone-Induced Demyelination Model
Rui Chang, BS, EMD Serono Research Institute Inc.; Shuning Huang, PhD, EMD Serono Research Institute Inc.; Anneli Savinainen, MS, EMD Serono Research Institute Inc.; Tim Crandall, BS, EMD Serono Research Institute Inc.; Danielle Graham, PhD, EMD Serono Research Institute Inc.; Joseph Mandeville, PhD, Athinoula A. Martinos Center for Biomedical Imaging - MGH; Ji-Kyung Choi, PhD, Athinoula A. Martinos Center for Biomedical Imaging - MGH; Bruce Jenkins, PhD, Athinoula A. Martinos Center for Biomedical Imaging - MGH; Guangping Dai, PhD, Athinoula A. Martinos Center for Biomedical Imaging - MGH; Tammy Dellovade, PhD, EMD Serono Research Institute Inc.

P17
The MS Support Group: Coping In Company With Chronic Illness
Allison R Fine, MSW, LICSW, Counseling for Inner Balance

P18
Co-Existing PML-IRIS and Myelitis In Neuromyelitis Optica Spectrum Disorder
Eoin P Flanagan, MB.BCh, Mayo Clinic; Allen J Aksamit, MD, Mayo Clinic; Neeraj Kumar, MD, Mayo Clinic; Neha P Morparia, MD, Mayo Clinic; B Mark Keegan, MD, Mayo Clinic; Brian G Weinshenker, MD, Mayo Clinic

P19
Reliability, Precision and Clinically Meaningful Change Of Fatigue Outcomes In MS
Yvonne C Learmonth, PhD, University of Illinois at Urbana-Champaign; Deirdre Dlugonski, BS, University of Illinois at Urbana-Champaign; Lara A Pilutti, PhD, University of Illinois at Urbana-Champaign; Brian M Sandroff, MS, University of Illinois at Urbana-Champaign; Robert W Motl, PhD, University of Illinois at Urbana-Champaign; Rachel E Klaren, BS, University of Illinois at Urbana-Champaign

P20
2-Year Follow-Up Results Of The HALT MS Clinical Trial (ITN033AI)
Richard A Nash, MD, Colorado Blood Cancer Institute at PSL; George J Hutton, MD, Baylor College of Medicine; Michael K Racke, MD, The Ohio State University Wexner Medical Center; Uday Popat, MD, MD Anderson Cancer Center; Steven M Devine, MD, The Ohio State University Wexner Medical Center; George E Georges, MD, Fred Hutchinson Cancer Research Center; Linda M Griffith, MD PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Paolo A Muraro, MD, Imperial College; Harry Openshaw, MD, City of Hope National Medical Center; Peter Sayre, MD, Immune Tolerance Network; Olaf Stuve, MD, University of Texas Southwestern Medical Center at Dallas; Douglas L Arnold, MD, Montreal Neurological Institute, McGill University, and NeuroRx Research, Montreal, Quebec, Canada; Meagan Spychala, DrPH, Rho Federal Systems Division, Inc; Noha Lim, PhD, Immune Tolerance Network; Sachin Malhotra, PhD, Immune Tolerance Network; Deborah Phippard, PhD, Immune Tolerance Network; Annette Wundes, MD, University of Washington; George H Kraft, MD, University of Washington; James D Bowen, MD, Swedish Medical Center

P21
Quantifying Balance and Its Relationship To Walking In Multiple Sclerosis
Scott D Newsome, D.O., Johns Hopkins School of Medicine; Rhul Marasigan, B.A., Kennedy Krieger Institute; Peter A Calabresi, MD, FAAN, Johns Hopkins School of Medicine; Kathleen M Zackowski, PhD, OT, Kennedy Krieger Institute

P23
Pediatric Tumefactive Multiple Sclerosis: Diagnostic & Treatment Challenges
Katherine D Standley, DO, University of South Florida

P24
Military Deployment and Risk For Multiple Sclerosis In The First Gulf War
Mitchell T Wallin, MD, MPH, MS Center of Excellence; Clare Mahan, PhD, Office of Public Health, Department of Veterans Affairs; Heidi Maloni, PhD, MS Center of Excellence; William J Culpepper II, PhD, MA, Baltimore VAMC; Parisa Coffman, BA, MS Center of Excellence; John F Kurtzke, MD, Georgetown University

P25
Leflunomide/Teriflunomide Differential Effects - Mitochondria and Hepatotoxicity
Emma-Jane Poulton, PhD, Sanofi; Timothy Ackerson, MS, Sanofi; Jacquelyn Dwyer, BS, Sanofi; Sandrine Turpault, PharmD, Sanofi; Lijuan Wang, PhD, Sanofi; Lynn Davenport, PhD, DABT, Sanofi; Zaid Jayyosi, PhD, Sanofi

P26
Vascular Iron Deposits Associate With Oxidative Injury in a Model of Multiple Sclerosis
Rachel Williams, Ph.D., University of Kansas Medical Center; Sylvester Marshall III, B.A., University of Kansas Medical Center; Steven M. LeVine, Ph.D., University of Kansas Medical Center

P27
Activated iNKT cells control CNS autoimmunity in a mechanism that involves MDSCs
Vrajesh V Parekh, Ph. D., Vanderbilt Medical Center; Lan Wu, M. D., Vanderbilt Medical Center; Danyvid Olivares-Villagomez, Ph. D., Vanderbilt Medical Center; Keith Wilson, M. D. , Ph. D., Vanderbilt Medical Center; Luc Van Kaer, Ph. D., Vanderbilt Medical Center

P29
Effects Of Exercise Training On Fatigue In Multiple Sclerosis: A Meta-Analysis
Lara A Pilutti, PhD, University of Illinois at Urbana-Champaign; Tina Greenlee, MS, University of Illinois at Urbana-Champaign; Robert W Motl, PhD, University of Illinois at Urbana-Champaign; Megan Nickrent, MS, University of Illinois at Urbana-Champaign; Steven J Petruzzello, PhD, University of Illinois at Urbana-Champaign


P31
Relative Efficacy of Teriflunomide 14 mg in Relapsing MS: A Mixed-Treatment Comparison
Gary Cutter, PhD, University of Alabama; Kyle Fahrbach, PhD, United BioSource Corporation; Rachel Huelin, BA, United BioSource Corporation; Erika Wissinger, PhD, United BioSource Corporation; Brice Kitio-Dschassi, X, Sanofi; Catherine Dive-Pouletty, PharmD, Sanofi; Patrick Vermersch, MD, PhD, University of Lille Nord de France

P32
Cost-Effectiveness of Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
Christine G. Kohn, PharmD, University of Connecticut; Victoria Costales, MD, Griffin Hospital; Craig I Coleman, PharmD, University of Connecticut; Dan Young, PharmD, University of Connecticut; Brendan L Limone, PharmD, University of Connecticut

P33
Effect of Interferon Beta-1a SC on Demyelination in Multiple Sclerosis Patients
Robert Zivadinov, MD, PhD, FAAN, State University of New York at Buffalo, Buffalo; Michael G Dwyer, MSc, State University of New York at Buffalo, Buffalo; Silva Markovic-Plese, MD, PhD, University of North Carolina at Chapel Hill; Cheryl Kennedy, LMSW, MPH, State University of New York at Buffalo, Buffalo; Niels Bergsland, MS, State University of New York at Buffalo, Buffalo; Deepa P Ramasamy, MD, State University of New York at Buffalo, Buffalo; Jacqueline Durfee, BS, State University of New York at Buffalo, Buffalo; David Hojnacki, MD, State University of New York at Buffalo, Buffalo; Brooke Hayward, SM, MBA,, EMD Serono, Inc.; Fernando Dangond, MD, FAAN, EMD Serono, Inc.; Bianca Weinstock-Guttman, MD, State University of New York at Buffalo, Buffalo

P34
Conservative Management of Hyperthyroidism Arising From Alemtuzumab Treatment in MS
Amel Arnaout, MD, FRCP, The Ottawa Hospital; Moebar Mahzari, MD, University of Ottawa; Mark Freedman, MD, University of Ottawa

P35
Chemical Exchange Saturation Transfer Imaging in Multiple Sclerosis
Craig Jones, PhD, Kennedy Krieger Institute; Chase Figley, BSc, Johns Hopkins University; Peter van Zijl, PhD, Johns Hopkins University; Peter A Calabresi, MD, FAAN, Johns Hopkins School of Medicine; Susan Courtney, PhD, Johns Hopkins University

P36
Interferon-Beta Reduces Mitochondrial Distress in EAE
Tapas K Makar, Ph.D., VA Maryland Health Care System; Vamshi Nimmagadda, M.B.B.S., University of Maryland School of Medicine; David Trisler, Ph.D., University of Maryland School of Medicine; Susan I Judge, Ph.D., University of Maryland School of Medicine; Naveen K Nagalla, MBBS, University of Maryland School of Medicine; Christopher T Bever Jr., M.D., M.B.A., VA Maryland Health Care System

P37
A Unique Tool for Studying Multiple Sclerosis: the Sonya Slifka Database
Sarah L Minden, MD, Brigham and Women's Hospital

P38
Sirtuin 1 in Experimental Allergic Encephalomyelitis
Vamshi Nimmagadda, M.B.B.S., University of Maryland School of Medicine; Tapas K Makar, Ph.D., University of Maryland School of Medicine; James W Russell, M.D., University of Maryland School of Medicine; Krish Chandrasekaran, Ph.D., University of Maryland School of Medicine; David Trisler, Ph.D., University of Maryland School of Medicine; Susan I Judge, Ph.D., VA Maryland Health Care System; Naveen K Nagalla, MBBS, University of Maryland School of Medicine; Christopher T Bever Jr., M.D., M.B.A., University of Maryland School of Medicine

P39
Effect of Interferon Beta-1a SC on Lesion Iron Content in Multiple Sclerosis
Robert Zivadinov, MD, PhD, FAAN, State University of New York at Buffalo, Buffalo; Silva Markovic-Plese, MD, PhD, University of North Carolina at Chapel Hill; Michael G Dwyer, MSc, State University of New York at Buffalo, Buffalo; Brooke Hayward, SM, MBA,, EMD Serono, Inc.; Niels Bergsland, MS, State University of New York at Buffalo, Buffalo; Mari Heininen-Brown, BA, State University of New York at Buffalo, Buffalo; Ellen Carl, MS, State University of New York at Buffalo, Buffalo; Cheryl Kennedy, LMSW, MPH, State University of New York at Buffalo, Buffalo; Fernando Dangond, MD, FAAN, EMD Serono, Inc.; Bianca Weinstock-Guttman, MD, State University of New York at Buffalo, Buffalo

P40
A Remyelinating Agent for Treatment of Multiple Sclerosis
Fengqiao Li, PhD, NeuroRepair Therapeutics, Inc.; Dale J. Christensen, PhD, NeuroRepair Therapeutics, Inc.; Michael P. Vitek, PhD, NeuroRepair Therapeutics, Inc.

P41
Intracortical Inhibition (ICI) and Facilitation (ICF) in Multiple Sclerosis (MS)
Marjan Zakeri, MD, The University of British Columbia; Alex MacKay, PhD, The University of British Columbia; Irene Vavasour, PhD, The University of British Columbia; Anthony L. Traboulsee, MD, The University of British Columbia; Lara Boyd, Phd, The University of British Columbia

P42
Clinical Outcomes and MS Diagnosis Criteria in the Combirx Trial
Khurram Bashir, MD, MPH, The University of Alabama at Birmingham; Stacey S Cofield, PhD, University of Alabama at Birmingham; Gary Cutter, PhD, University of Alabama at Birmingham; Jerry Wolinsky, MD, The University of Texas Health Science Center at Houston; Tarah Gustafson, BSN, Corinne Goldsmith Dickinson Center for Multiple Sclerosis; Robin Conwit, MD, NIH; Amber Salter, MPH, University of Alabama at Birmingham; Jing Wang, MS, University of Alabama at Birmingham; Fred D. Lublin, MD, Corinne Goldsmith Dickinson Center for Multiple Sclerosis

P43
Deep Sequencing of Primary Progressive Multiple Sclerosis and Encephaltitis Brain
John D Kriesel, MD, University of Utah School of Medicine; Benjamin K Chan, PhD, University of Utah School of Medicine; Theodore Wilson, BA, University of Utah School of Medicine; Kael F Fischer, PhD, University of Utah School of Medicine

P47
Unexpected Retinal Abnormalities Detected Upon Evaluation for Neurological Disease
Elias S Sotirchos, MD, Johns Hopkins University; Angela Vidal-Jordana, MD, Vall díHebron University Hospital; Shiv Saidha, MD, Johns Hopkins University; Yasir Sepah, MBBS, Johns Hopkins University; John N Ratchford, MD, Johns Hopkins University; Quan Dong Nguyen, MD, Johns Hopkins University; Elliot Frohman, MD, PhD, FAAN, UT Southwestern Medical Center; Laura J Balcer, MD, MSCE, New York University; Peter A Calabresi, MD, FAAN, Johns Hopkins University; Scott D Newsome, D.O., Johns Hopkins University

P48
HHV6 IgG Response and Genetic Factor rs11154801 Associate With Relapse Rate in Children
Jennifer Graves, MD, PhD, University of California, San Francisco; Lisa Barcellos, PhD, University of California, Berkeley; Lauren Krupp, MD, Stony Brook University Medical Center; Anita L Belman, MD, Stony Brook University Medical Center; Judith A James, MD, Oklahoma Medical Research Foundation, University of Oklahoma; Emmanuelle Waubant, MD, PhD, University of California, San Francisco

P49
Determining Response to Treatment With Rituximab in Relapsing Multiple Sclerosis
Enrique Alvarez, MD/PhD, Washington University School of Medicine in St. Louis; Laura Piccio, MD/PhD, Washington University School of Medicine in St. Louis; Robert J Mikesell, BS, Washington University School of Medicine in St. Louis; Kim Trinkaus, PhD, Washington University School of Medicine in St. Louis; Nhial Tutlam, MPH, Washington University School of Medicine in St. Louis; Michael J Ramsbottom, BS, Washington University School of Medicine in St. Louis; Neville Rapp, PhD, Washington University School of Medicine in St. Louis; Samantha Lancia, MS, Washington University School of Medicine in St. Louis; Becky J Parks, MD, Washington University School of Medicine in St. Louis; Robert T Naismith, MD, Washington University School of Medicine in St. Louis; Anne H Cross, MD, Washington University School of Medicine in St. Louis

P50
Circumstances Surrounding Falls in Individuals With Multiple Sclerosis
Moira Baynes, RN, Johns Hopkins University; Scott D Newsome, D.O., Johns Hopkins School of Medicine; Dorlan Kimbrough, MD, Johns Hopkins University; Peter A Calabresi, MD, FAAN, Johns Hopkins University; Kathleen M Zackowski, PhD, OT, Johns Hopkins School of Medicine

P51
Predictors of Acceptance of Using Games for Cognitive Rehabilitation
Joseph Finkelstein, MD, PhD, Baltimore VA Medical Center; Elisa Ochfeld, BS, Baltimore VA Medical Center; Eunme Cha, MPH, Baltimore VA Medical Center; Walter Royal, MD, Baltimore VA Medical Center

See more of: ACTRIMS